Oppenheimer set a $12.00 price objective on Teva Pharmaceutical Industries (NYSE:TEVA) in a research report sent to investors on Wednesday, TipRanks reports. The brokerage currently has a buy rating on the stock.
Several other research firms have also weighed in on TEVA. Mizuho lowered shares of Teva Pharmaceutical Industries from a buy rating to a neutral rating and lowered their target price for the stock from $25.00 to $18.00 in a report on Wednesday, February 20th. Citigroup lowered their target price on shares of Teva Pharmaceutical Industries from $27.00 to $23.00 and set a buy rating on the stock in a report on Thursday, April 11th. BMO Capital Markets started coverage on shares of Teva Pharmaceutical Industries in a report on Thursday, March 28th. They issued a market perform rating and a $18.00 target price on the stock. Wells Fargo & Co reaffirmed a hold rating on shares of Teva Pharmaceutical Industries in a report on Friday, May 10th. Finally, Morgan Stanley set a $16.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a hold rating in a report on Friday, May 3rd. Five analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Hold and an average price target of $17.05.
TEVA opened at $8.24 on Wednesday. The company has a debt-to-equity ratio of 1.66, a quick ratio of 0.62 and a current ratio of 0.96. Teva Pharmaceutical Industries has a twelve month low of $8.19 and a twelve month high of $25.96. The stock has a market capitalization of $8.86 billion, a PE ratio of 2.94, a PEG ratio of 1.05 and a beta of 1.64.
In related news, Director Sol J. Barer purchased 111,000 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Monday, June 3rd. The shares were acquired at an average price of $8.98 per share, for a total transaction of $996,780.00. Following the transaction, the director now directly owns 115,942 shares in the company, valued at $1,041,159.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Notaristefani Carlo De sold 16,070 shares of the company’s stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $11.42, for a total transaction of $183,519.40. Following the transaction, the vice president now owns 49,659 shares in the company, valued at approximately $567,105.78. The disclosure for this sale can be found here. In the last quarter, insiders have sold 18,860 shares of company stock worth $226,854. 0.49% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Kore Private Wealth LLC acquired a new position in Teva Pharmaceutical Industries during the 1st quarter valued at about $29,000. Coastal Investment Advisors Inc. acquired a new position in Teva Pharmaceutical Industries during the 1st quarter valued at about $37,000. Bruderman Asset Management LLC lifted its position in Teva Pharmaceutical Industries by 2,175.0% during the 4th quarter. Bruderman Asset Management LLC now owns 2,366 shares of the company’s stock valued at $36,000 after purchasing an additional 2,262 shares during the period. Lindbrook Capital LLC lifted its position in Teva Pharmaceutical Industries by 61.2% during the 1st quarter. Lindbrook Capital LLC now owns 2,489 shares of the company’s stock valued at $39,000 after purchasing an additional 945 shares during the period. Finally, Cullen Frost Bankers Inc. acquired a new position in Teva Pharmaceutical Industries during the 1st quarter valued at about $40,000. Institutional investors and hedge funds own 65.10% of the company’s stock.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Read More: What is the return on assets formula?
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.